New targets for mucosal healing and therapy in inflammatory bowel diseases - PubMed (original) (raw)

Review

doi: 10.1038/mi.2013.73. Epub 2013 Oct 2.

Affiliations

Free article

Review

New targets for mucosal healing and therapy in inflammatory bowel diseases

M F Neurath. Mucosal Immunol. 2014 Jan.

Free article

Abstract

Healing of the inflamed mucosa (mucosal healing) is an emerging new goal for therapy and predicts clinical remission and resection-free survival in inflammatory bowel diseases (IBDs). The era of antitumor necrosis factor (TNF) antibody therapy was a remarkable progress in IBD therapy and anti-TNF agents led to mucosal healing in a subgroup of IBD patients; however, many patients do not respond to anti-TNF treatment highlighting the relevance of finding new targets for therapy of IBD. In particular, current studies are addressing the role of other anticytokine agents including antibodies against interleukin (IL)-6R, IL-13, and IL-12/IL-23 as well as new anti-inflammatory concepts (regulatory T cell therapy, Smad7 antisense, Jak inhibition, Toll-like receptor 9 stimulation, worm eggs). In addition, blockade of T-cell homing via the integrins α4β7 and the addressin mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) emerges as a promising new approach for IBD therapy. Here, new approaches for achieving mucosal healing are discussed as well as their implications for future therapy of IBD.

PubMed Disclaimer

Similar articles

Cited by

References

    1. N Engl J Med. 2012 Mar 29;366(13):1181-9 - PubMed
    1. Am J Physiol. 1998 May;274(5):G809-18 - PubMed
    1. Lab Invest. 2007 Aug;87(8):807-17 - PubMed
    1. J Cell Biochem. 2008 Aug 15;104(6):2286-97 - PubMed
    1. Am J Physiol Regul Integr Comp Physiol. 2001 Oct;281(4):R1264-73 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources